KIT and gastrointestinal stromal tumor: Dasatinib exhibited a 71% RR in patients with KIT/PDGFRA wild-type GIST in TKI-naïve patients [48], while wild-type GIST patients treated with sunitinib in the second-line or beyond exhibited longer PFS compared to patients with KIT exon 11 mutated tumours [51].